Literature DB >> 904003

Cytotoxicity inhibition assay: cryopreservation and standardization: brief communication.

R K Oldham, J R Ortaldo, H T Holden, R B Herberman.   

Abstract

The cytotoxicity inhibition assay is an extremely useful tool for examination of the specificity of cell-mediated cytotoxicity. With this demonstration of cryopreservation of the attacker, target, and inhibitor cells, a powerful new tool is available for the standardization of this assay to better examine the specificity of cytotoxicity assays. Not only can cryopreservation be used to standardize the assay within a single laboratory, but also reagents may now be exchanged between laboratories to better understand the differences in cell-mediated cytotoxicity as observed by different investigators.

Entities:  

Mesh:

Year:  1977        PMID: 904003     DOI: 10.1093/jnci/59.4.1321

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  Immunological studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer.

Authors:  R K Oldham; M H Gail; M A Baker; J T Forbes; W Heineman; E Hersh; E C Holmes; R E Ritts; P W Wright
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

2.  Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity.

Authors:  J T Forbes; R K Bretthauer; T N Oeltmann
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

3.  Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.

Authors:  J L Urban; R C Burton; J M Holland; M L Kripke; H Schreiber
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

4.  Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation.

Authors:  J L Urban; J M Holland; M L Kripke; H Schreiber
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

5.  Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity.

Authors:  J L Urban; H Schreiber
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.